Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Promising combo for Hard-to-Treat prostate cancer enters first human tests

NCT ID NCT07316686

Not yet recruiting Disease control Sponsor: Instituto do Cancer do Estado de São Paulo Source: ClinicalTrials.gov ↗

First seen Jan 09, 2026 · Last updated May 24, 2026 · Updated 23 times

Summary

This early-phase study tests a combination of chemotherapy (docetaxel) and a targeted radioactive drug (177Lu-PSMA) in 18 men with advanced prostate cancer that has stopped responding to hormone therapy. The main goal is to find the safest dose of the chemotherapy when given with the radioactive drug. Participants will receive both treatments along with standard hormone therapy. The study aims to control the disease, not cure it, as ongoing treatment is needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER (ADENOCARCINOMA) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Instituto do Câncer do Estado de São Paulo - ICESP

    São Paulo, 01246000, Brazil

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

PROSTATE CANCER (ADENOCARCINOMA)